MARKET

TGTX

TGTX

Tg Therapeutics Inc
NASDAQ
13.53
+0.17
+1.27%
Opening 09:57 02/27 EST
OPEN
13.82
PREV CLOSE
13.36
HIGH
13.86
LOW
13.36
VOLUME
581.60K
TURNOVER
0
52 WEEK HIGH
35.67
52 WEEK LOW
6.46
MARKET CAP
2.05B
P/E (TTM)
-49.7976
1D
5D
1M
3M
1Y
5Y
TG Therapeutics: Promising European Expansion and Strong Financial Outlook Justify Buy Rating
TipRanks · 23h ago
TG Therapeutics' Briumvi Launched In Europe
NASDAQ · 1d ago
Weekly Report: what happened at TGTX last week (0219-0223)?
Weekly Report · 1d ago
TG Therapeutics Announces European Launch of BRIUMVI (Ublituximab-xiiy), Bags a Milestone Payment of $12.5M
TG Therapeutics launches BRIUMVI in Europe for the treatment of adults with relapsing forms of multiple sclerosis. The launch commenced in Germany. The company's ex-US partner, Neuraxpharm Group, will receive a milestone payment of $12.5 million.
Benzinga · 1d ago
TG Therapeutics (TGTX) Price Target Increased by 5.80% to 30.89
NASDAQ · 3d ago
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
TG Therapeutics, Inc. Will hold a conference call on February 28, 2024, to discuss results for the fourth quarter and year-end 2023 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
Barchart · 4d ago
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
NASDAQ · 5d ago
PTON, PLUG, and CAR are some of the high beta losers to Sell according to Oppenheimer
On the Move PTON, PLUG, and CAR are some of the high beta losers to Sell according to Oppenheimer. Financial firm highlighted a group of vulnerable high beta loser stocks that it thinks are primed for investors to sell according to specific technical levels. The eight stocks are listed as high-beta losers to sell by the financial firm.
Seeking Alpha · 6d ago
More
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Webull offers TG Therapeutics Inc stock information, including NASDAQ: TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.